Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Moodys
McKinsey
Harvard Business School
Johnson and Johnson
Express Scripts

Last Updated: November 29, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR RUXOLITINIB PHOSPHATE

➤ Subscribe for complete access

« Back to Dashboard

All Clinical Trials for ruxolitinib phosphate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00778700 ↗ A Dose Ranging Study of the Effect of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Psoriasis Completed Incyte Corporation Phase 2 2008-10-01 The study will be a double-blind, randomized, vehicle-controlled study with application of ruxolitinib phosphate cream or vehicle in patients with stable plaque psoriasis. Application will be QD for 12 weeks without occlusive dressings. There will be 4 treatments of 50 subjects each.
NCT00820950 ↗ A Study of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Psoriasis Completed Incyte Corporation Phase 2 2007-05-01 The study is comprised of two parts. The first portion of this study will be a double-blind, Sponsor-unblinded, vehicle-controlled study with application of ruxolitinib or vehicle to paired lesions at least 15 cm apart in patients with active but stable plaque psoriasis. Part 2 of the study is a double-blind, sponsor unblinded, comparison of ruxolitinib with two FDA approved products in patients with active but stable plaque psoriasis.
NCT01164163 ↗ INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease Completed National Cancer Institute (NCI) Phase 1 2010-09-01 RATIONALE: INCB18424 (Ruxolitinib) may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase 1 clinical trial is studying the side effects and best dose of INCB18424 in treating young patients with relapsed or refractory solid tumor, leukemia, or myeloproliferative disease.
NCT01164163 ↗ INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease Completed Children's Oncology Group Phase 1 2010-09-01 RATIONALE: INCB18424 (Ruxolitinib) may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase 1 clinical trial is studying the side effects and best dose of INCB18424 in treating young patients with relapsed or refractory solid tumor, leukemia, or myeloproliferative disease.
NCT01431209 ↗ Ruxolitinib Phosphate in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma After Donor Stem Cell Transplant Completed Incyte Corporation Phase 2 2011-08-01 This phase II trial studies how well ruxolitinib phosphate works in treating patients with diffuse large B-cell or peripheral T-cell non-Hodgkin lymphoma that has returned (relapsed) or that does not respond to treatment (refractory) after donor stem cell transplant. Ruxolitinib phosphate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
NCT01431209 ↗ Ruxolitinib Phosphate in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma After Donor Stem Cell Transplant Completed National Cancer Institute (NCI) Phase 2 2011-08-01 This phase II trial studies how well ruxolitinib phosphate works in treating patients with diffuse large B-cell or peripheral T-cell non-Hodgkin lymphoma that has returned (relapsed) or that does not respond to treatment (refractory) after donor stem cell transplant. Ruxolitinib phosphate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for ruxolitinib phosphate

Condition Name

Condition Name for ruxolitinib phosphate
Intervention Trials
Primary Myelofibrosis 5
Leukemia 5
Secondary Myelofibrosis 4
Refractory Acute Myeloid Leukemia 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for ruxolitinib phosphate
Intervention Trials
Leukemia 10
Leukemia, Myeloid 6
Neoplasms 5
Primary Myelofibrosis 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for ruxolitinib phosphate

Trials by Country

Trials by Country for ruxolitinib phosphate
Location Trials
United States 188
Canada 5
China 1
Germany 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for ruxolitinib phosphate
Location Trials
Texas 14
California 10
Oregon 8
Minnesota 8
New York 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for ruxolitinib phosphate

Clinical Trial Phase

Clinical Trial Phase for ruxolitinib phosphate
Clinical Trial Phase Trials
Phase 4 1
Phase 2 15
Phase 1/Phase 2 2
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for ruxolitinib phosphate
Clinical Trial Phase Trials
Completed 13
Recruiting 8
Active, not recruiting 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for ruxolitinib phosphate

Sponsor Name

Sponsor Name for ruxolitinib phosphate
Sponsor Trials
National Cancer Institute (NCI) 18
Incyte Corporation 13
M.D. Anderson Cancer Center 5
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for ruxolitinib phosphate
Sponsor Trials
Other 22
NIH 19
Industry 13
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
McKesson
McKinsey
Harvard Business School
Merck
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.